Hepatic impairment No dose adjustment is required in individuals with gentle or reasonable (Youngster-Pugh A or B) hepatic impairment (see segment 5.2). Exposure to midostaurin and its active metabolite CGP62221 is significantly lessen in people with intense hepatic impairment than that in clients with usual hepatic purpose (see part five.NSC 62850… Read More